Stock Track | Hims & Hers Soars Over 5% as Makary FDA Pick Boosts Prospects for Compounded Drug Sales

Stock Track11-26

Shares of Hims & Hers Health Inc. (HIMS) soared 5.14% on Monday after President-elect Donald Trump nominated Dr. Marty Makary to lead the Food and Drug Administration (FDA), boosting optimism about the company's prospects for selling compounded versions of popular weight-loss drugs.

Makary, a surgeon and chief medical officer for telehealth provider Sesame, has ties to the compounding pharmacy industry that offers alternatives to brand-name drugs like Novo Nordisk's Wegovy. Hims & Hers is among the telehealth companies benefiting from surging demand for compounded versions of Wegovy due to shortages and high costs of the branded drug.

With Makary's nomination, investors are betting that the new administration could adopt a more favorable stance toward compounding pharmacies, potentially allowing them to expand production of alternatives to expensive drugs. This could further boost demand for Hims & Hers' compounded offerings and drive growth for the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123830711?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-26 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123830711","market":"hk","top_or_hot":-1,"title":"Stock Track | Hims & Hers Soars Over 5% as Makary FDA Pick Boosts Prospects for Compounded Drug Sales","media":"Stock Track","content":"<p>Shares of Hims & Hers Health Inc. (HIMS) soared 5.14% on Monday after President-elect Donald Trump nominated Dr. Marty Makary to lead the Food and Drug Administration (FDA), boosting optimism about the company's prospects for selling compounded versions of popular weight-loss drugs.</p>\n\n<p>Makary, a surgeon and chief medical officer for telehealth provider Sesame, has ties to the compounding pharmacy industry that offers alternatives to brand-name drugs like Novo Nordisk's Wegovy. Hims & Hers is among the telehealth companies benefiting from surging demand for compounded versions of Wegovy due to shortages and high costs of the branded drug.</p>\n\n<p>With Makary's nomination, investors are betting that the new administration could adopt a more favorable stance toward compounding pharmacies, potentially allowing them to expand production of alternatives to expensive drugs. This could further boost demand for Hims & Hers' compounded offerings and drive growth for the company.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Soars Over 5% as Makary FDA Pick Boosts Prospects for Compounded Drug Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Soars Over 5% as Makary FDA Pick Boosts Prospects for Compounded Drug Sales\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-26 09:36 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Hims & Hers Health Inc. (HIMS) soared 5.14% on Monday after President-elect Donald Trump nominated Dr. Marty Makary to lead the Food and Drug Administration (FDA), boosting optimism about ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1123830711","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123830711","pubTimestamp":1732585013,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Hims & Hers Health Inc.  soared 5.14% on Monday after President-elect Donald Trump nominated Dr. Marty Makary to lead the Food and Drug Administration , boosting optimism about the company's prospects for selling compounded versions of popular weight-loss drugs.Makary, a surgeon and chief medical officer for telehealth provider Sesame, has ties to the compounding pharmacy industry that offers alternatives to brand-name drugs like Novo Nordisk's Wegovy. Hims & Hers is among the teleheal","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"Makary FDA选择提振复合药物销售前景，Hims&Hers股价飙升超过5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Shares of Hims & Hers Health Inc. (HIMS) soared 5.14% on Monday after President-elect Donald Trump nominated Dr. Marty Makary to lead the Food and Drug Administration (FDA), boosting optimism about the company's prospects for selling compounded versions of popular weight-loss drugs.\nMakary, a surgeon and chief medical officer for telehealth provider Sesame, has ties to the compounding pharmacy industry that offers alternatives to brand-name drugs like Novo Nordisk's Wegovy. Hims & Hers is among the telehealth companies benefiting from surging demand for compounded versions of Wegovy due to shortages and high costs of the branded drug.\nWith Makary's nomination, investors are betting that the new administration could adopt a more favorable stance toward compounding pharmacies, potentially allowing them to expand production of alternatives to expensive drugs. This could further boost demand for Hims & Hers' compounded offerings and drive growth for the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123830711"}